Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.46 |
| ▸ | LPL | P06858 | 8/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374243 | 1.00 | LIPG (0.46) | LIPGLPLTRPV1MGLLCA1 | |
| SCHEMBL5809203 | 1.00 | LIPG (0.46) | LIPGLPLTRPV1MGLLCA1 | |
| SCHEMBL29383962 | 1.00 | LIPG (0.46) | LIPGLPLTRPV1MGLLCA1 | |
| SCHEMBL766656 | 1.00 | LIPG (0.46) | LIPGLPLTRPV1MGLLCA1 | |
| SCHEMBL28537539 | 1.00 | LIPG (0.46) | LIPGLPLTRPV1MGLLCA1 | |
| SCHEMBL29460237 | 1.00 | LIPG (0.46) | LIPGLPLTRPV1MGLLCA1 | |
| SCHEMBL29453590 | 1.00 | LIPG (0.46) | LIPGLPLTRPV1MGLLCA1 | |
| SCHEMBL6446324 | 0.98 | LIPG (0.45) | LIPGLPLTRPV1MGLLCA1 | |
| Ethylene Glycol SCHEMBL588016 | 0.96 | LIPG (0.43) | LIPGLPLTRPV1MGLLCA1 | |
| 1,3-Propanediol SCHEMBL23298331 | 0.94 | LIPG (0.42) | LIPGLPLTRPV1MGLLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| CN-114149568-A | Preparation method of polyfluorene material and obtained polyfluorene material | 北京化工大学 | 2022-03-08 | — | — | CN | disclosed |
| US-8921836-B2 | Polymer compound, and thin film and ink composition each containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8921836-B2 | Polymer compound, and thin film and ink composition each containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120305899-A1 | POLYMER COMPOUND, AND THIN FILM AND INK COMPOSITION EACH CONTAINING SAME | NATIONAL UNIVERSITY OF CORPORATION HIROSHIMA UNIVERSITY (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8298686-B2 | Composition and organic photoelectric converter using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8298686-B2 | Composition and organic photoelectric converter using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8207337-B2 | Reagent for organic synthesis reaction containing organic triol borate salt | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110127515-A1 | PHOTOELECTRIC CONVERSION ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2327734-A1 | POLYMER COMPOUND AND POLYMER LIGHT-EMITTING ELEMENT UTILIZING SAME | Sumitomo Chemical Company, Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20100327271-A1 | COMPOSITION AND ORGANIC PHOTOELECTRIC CONVERTER USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100327271-A1 | COMPOSITION AND ORGANIC PHOTOELECTRIC CONVERTER USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100087646-A1 | REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | LIPG 1131/4885LPL 3998/4885TRPV1 2974/4885 |
| US-20100087646-A1 | REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT | ORC3, OXSR1, OSTC | LIPG 4397/4885LPL 3426/4885TRPV1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.